AI Proteins, Inc. is pioneering the development of miniproteins, which are engineered to possess ideal therapeutic characteristics for protein-based medicines. Their proprietary platform integrates synthetic biology, robotics, automation, and artificial intelligence to facilitate the rapid design and production of these miniproteins. This innovative approach allows for the creation of highly specific, durable, and cost-effective therapeutic candidates that can be tailored for various administration routes. The company emphasizes the advantages of their de novo design capabilities, which provide complete structural control over the miniproteins, enabling the combination of beneficial traits from both small molecules and biologics. This versatility positions AI Proteins to target a wide range of therapeutic areas, including oncology, inflammation, and metabolic diseases.

The miniproteins developed by AI Proteins are characterized by their stability, specificity, and non-immunogenic properties, making them an attractive next-generation therapeutic modality. These peptides are designed to fold into stable structures, resist degradation, and exhibit high solubility, which enhances their therapeutic potential. The company employs advanced techniques such as yeast and phage display for screening, alongside automated production and biophysical characterization methods to optimize their candidates. Their unique approach, which includes deep saturation mutagenesis and targeted design, allows for the rapid identification and refinement of miniproteins, ensuring that drug-like properties are integrated from the outset. With a robust pipeline and proof of concept data for multiple high-value targets, AI Proteins is well-positioned to advance the future of protein therapeutics.

United States

Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND enabling studies.

AI Proteins, Inc.

Company Details